Nothing said here yet.
to join the conversation.
| Anderman ToddChief Legal Officer | Sell | 11,984 | $87.4K | Thu, Oct 8 |
| Heier Jeffrey S.Chief Scientific Officer | Sell | 10,869 | $76.6K | Fri, Oct 2 |
| Kaiser PeterChief Development Officer | Sell | 9,990 | $70.4K | Fri, Oct 2 |
| Notman DonaldChief Operating Officer | Sell | 1,099 | $11.3K | Mon, Aug 31 |
| Dugel PravinSee Remarks | Sell | 21,649 | $233.2K | Mon, Aug 24 |
| Heier Jeffrey S.Chief Scientific Officer | Sell | 3,296 | $35.5K | Mon, Aug 24 |
| Kaiser PeterChief Development Officer | Sell | 3,035 | $32.7K | Mon, Aug 24 |
| Nayak SanjayChief Strategy Officer | Sell | 1,897 | $20.4K | Mon, Aug 24 |
Ocular Therapeutix (NASDAQ:OCUL) is preparing a fourth-quarter new drug application submission for AXPAXLI, its investigational maintenance treatment for wet age-related macular degeneration, following discussions with the U.S. Food and Drug Administration,…
Ocular Therapeutix has delivered a steep 144.6% gain over the past three years, yet the stock is currently well off recent highs.
OCUL stock selloff began on Monday after Kodiak Sciences and 4D Molecular posted updates from clinical trials of their eye-disease drugs.
Over the last six months, Ocular Therapeutix’s shares have sunk to $7.74, producing a disappointing 7.1% loss - a stark contrast to the S&P 500’s 16.6% gain. This might have investors contemplating their next move.
In the high-stakes realm of clinical-stage biotechnology, long-term shareholder value is fundamentally forged by pipeline assets that solve deep-seated clinical bottlenecks while offering significant pricing power and capital efficiency.
Ocular Therapeutix (NASDAQ:OCUL) said it remains on track to submit a U.S.
On August 3, Ocular Therapeutix (NASDAQ:OCUL) reported second-quarter 2026 financial results that read as much like a regulatory update as an earnings report.